Nature Communications (Jun 2021)
Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2
- Yusuke Higuchi,
- Tatsuya Suzuki,
- Takao Arimori,
- Nariko Ikemura,
- Emiko Mihara,
- Yuhei Kirita,
- Eriko Ohgitani,
- Osam Mazda,
- Daisuke Motooka,
- Shota Nakamura,
- Yusuke Sakai,
- Yumi Itoh,
- Fuminori Sugihara,
- Yoshiharu Matsuura,
- Satoaki Matoba,
- Toru Okamoto,
- Junichi Takagi,
- Atsushi Hoshino
Affiliations
- Yusuke Higuchi
- Department of Cardiovascular Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine
- Tatsuya Suzuki
- Institute for Advanced Co-Creation Studies, Research Institute for Microbial Diseases, Osaka University
- Takao Arimori
- Laboratory for Protein Synthesis and Expression, Institute for Protein Research, Osaka University
- Nariko Ikemura
- Department of Cardiovascular Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine
- Emiko Mihara
- Laboratory for Protein Synthesis and Expression, Institute for Protein Research, Osaka University
- Yuhei Kirita
- Department of Nephrology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine
- Eriko Ohgitani
- Department of Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine
- Osam Mazda
- Department of Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine
- Daisuke Motooka
- Department of Infection Metagenomics, Research Institute for Microbial Diseases, Osaka University
- Shota Nakamura
- Department of Infection Metagenomics, Research Institute for Microbial Diseases, Osaka University
- Yusuke Sakai
- Department of Veterinary Pathology, Yamaguchi University
- Yumi Itoh
- Institute for Advanced Co-Creation Studies, Research Institute for Microbial Diseases, Osaka University
- Fuminori Sugihara
- The Core Instrumentation Facility, Research Institute for Microbial Diseases, Osaka University
- Yoshiharu Matsuura
- Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University
- Satoaki Matoba
- Department of Cardiovascular Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine
- Toru Okamoto
- Institute for Advanced Co-Creation Studies, Research Institute for Microbial Diseases, Osaka University
- Junichi Takagi
- Laboratory for Protein Synthesis and Expression, Institute for Protein Research, Osaka University
- Atsushi Hoshino
- Department of Cardiovascular Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine
- DOI
- https://doi.org/10.1038/s41467-021-24013-y
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 13
Abstract
Hoshino et al., engineer a human virus receptor, hACE2, and demonstrate its potential for overcoming SARS-CoV-2 mutations that otherwise hinder therapeutic interventions. Overall, the data provide insights in to the therapeutic potential of engineered receptors.
